IEX6014 / Innovent Biologics - LARVOL DELTA

Development and Characterization of IEX6014, A Novel IL-6 x TL1A BsAb, With Broader and Deeper Inhibition of Disease-driving Mechanisms (ACR Convergence 2026) - "The IL-6 binder was engineered from Olokizumab, targeting a unique epitope...IEX6014 demonstrates superior or comparable blockade of TL1A signaling in DR3-NFκB reporter assay and primary T cell activation assay, compared to MK-7240 and RVT-3101. IEX6014 demonstrates superior blockade of IL-6 signaling induced by either IL-6 or IL-6/IL-6R complex, compared to Tocilizumab... The 2+2 and 1+1 geometry design of IEX6014 confers the BsAb with potent IL-6 and TL1A blockade, meanwhile avoids the formation of large immune complex, a mechanism increasing ADA risk associated with biologics targeting TNF family members. The favorable PK and developability profile enable the potential for patient-friendly convenience with s.c. administration and less frequent dosing. All above features position IEX6014 as a best-in-disease RA therapeutic regent."

Bispecific • Immunology • Inflammation • Inflammatory Arthritis • Rheumatoid Arthritis • IL6 • IL6R